Novo Nordisk A/S is slashing its workforce by 11% and pledging to move faster to catch up with Eli Lilly & Co. in the obesity market. That may mean making the company more like its US rival. Novo’s new “performance culture,” as the recently installed Chief Executive Officer Maziar Mike Doustdar put it, will probably mean a focus on return to office for workers, faster decision-making and slashing support staff and middle management, analysts said Wednesday. The shift is a stark contrast to his predecessor’s ...